Idexx Laboratories (IDXX) EBT (2009 - 2026)

Idexx Laboratories has reported EBT for 18 years, with the latest figure at $417.2 million in Q2 2026.

• On a quarterly basis, EBT rose 15.14% year-over-year to $417.2 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 16.02% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 19.31% from the prior year.
• EBT was $417.2 million for Q2 2026 at Idexx Laboratories, up from $355.4 million in the prior quarter.
• The five-year high for EBT was $417.2 million in Q2 2026, with the low at $171.1 million in Q2 2022.
• Average EBT over 5 years is $284.9 million, with a median of $276.9 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: EBT sank 32.04% in 2022, then jumped 67.13% in 2023.
• Over 5 years, EBT stood at $213.2 million in 2022, then gained by 12.41% to $239.7 million in 2023, then climbed by 6.98% to $256.4 million in 2024, then rose by 19.73% to $307.0 million in 2025, then jumped by 35.91% to $417.2 million in 2026.
• The last three EBT figures came in at $417.2 million (Q2 2026), $355.4 million (Q1 2026), and $307.0 million (Q4 2025), per Business Quant data.